Dr. Harold J. Burstein, MD, PhD: Boston’s Leading Breast Cancer Oncologist at Dana-Farber

Breast cancer is the most commonly diagnosed cancer in American women and one of the most researched diseases in medicine. Even within that crowded field, Dr. Harold J. Burstein stands out. Over more than two decades at Dana-Farber Cancer Institute, he has become one of the most cited breast cancer researchers in the world, a principal figure in setting the international treatment guidelines that determine how breast cancer is managed in major centers globally, and a perennial Top Doctor recognized year after year by peers across the United States.

Named to the Boston Magazine Top Doctors 2026 list, Dr. Burstein practices within the Breast Oncology Center at Dana-Farber’s Susan F. Smith Center for Women’s Cancers, one of the largest and most comprehensive breast cancer programs in the country. His patient care, research, and guideline work span every stage and subtype of breast cancer, from early-stage localized disease to advanced metastatic breast cancer.

An Unusual Academic Pedigree

Dr. Burstein’s academic background is genuinely uncommon in clinical medicine. He attended Harvard College before earning his MD at Harvard Medical School, where he simultaneously pursued a PhD in cellular immunology. He also holds a master’s degree in the history of science from Harvard — a credential that signals both intellectual range and a thoughtful approach to how science evolves and gets translated into clinical practice.

He completed his internal medicine residency at Massachusetts General Hospital, one of the most competitive residency programs in the country, before training in medical oncology at Dana-Farber itself — the institution where he has spent his entire career since joining the staff in 1999.

His research has been published in the New England Journal of Medicine, the Journal of Clinical Oncology, and other leading medical journals, and his publication record has accumulated more than 39,000 citations — a number that places him among the most influential clinical researchers in oncology worldwide.

Clinical Expertise: Breast Cancer Across Every Stage

Dr. Burstein’s clinical practice covers the full spectrum of breast cancer diagnosis and treatment. His areas of particular expertise include HER2-positive breast cancer, hormone receptor-positive breast cancer, early-stage breast cancer management, and the treatment of metastatic breast cancer. He has been a key contributor to the understanding of how different molecular subtypes of breast cancer respond to different therapies, and he has led or participated in the clinical trials that established many of the treatments now considered standard of care.

His work on HER2-positive breast cancer has been especially influential. He published landmark early studies on the use of trastuzumab combined with paclitaxel in the neoadjuvant setting — before surgery — establishing preoperative systemic therapy as a productive model for studying breast cancer biology and testing new treatments. His 2005 paper in the New England Journal of Medicine on the distinctive nature of HER2-positive breast cancer is one of the foundational references in that subtype’s clinical management.

He has also contributed extensively to the understanding of endocrine therapy in hormone receptor-positive breast cancer — studying the optimal sequencing of tamoxifen and aromatase inhibitors, ovarian suppression in premenopausal women, and extended adjuvant therapy strategies. Research from his group and collaborating institutions has shaped how premenopausal women with early-stage breast cancer are treated globally.

Shaping Global Treatment Guidelines

One of the most significant aspects of Dr. Burstein’s career is his sustained role in developing the international guidelines that determine how breast cancer is treated far beyond Boston. He has served on the National Comprehensive Cancer Network Breast Cancer Panel, which produces the NCCN Guidelines used by oncologists across the United States as the primary reference for treatment decisions. He has been a member of the St. Gallen International Breast Cancer Panel, which every two years produces consensus guidelines followed by oncologists in Europe, Asia, and worldwide.

He has also served on expert panels for the American Society of Clinical Oncology and multiple other professional bodies. This means that when a breast cancer oncologist in Chicago, Munich, or Tokyo consults their treatment guidelines, they are reading recommendations that Dr. Burstein helped write, debate, and refine. The reach of his influence extends far beyond his direct patient care and his own clinical trials.

In 2025, the St. Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer included Dr. Burstein among its contributing authors — continuing a decades-long involvement in shaping how the global oncology community approaches early-stage disease.

Research Focus and Active Investigations

Dr. Burstein’s current research spans several intersecting areas of breast cancer biology and treatment. He is a principal investigator and collaborator on the PACE trial, a phase II randomized study evaluating strategies for patients with hormone receptor-positive, HER2-negative metastatic breast cancer who have progressed on CDK4/6 inhibitors — one of the most pressing clinical challenges in metastatic breast cancer management now that CDK4/6 inhibitors have become first-line therapy.

His laboratory interests include the study of circulating tumor DNA as a biomarker for treatment response and resistance, quality of life and health behavior research in women with breast cancer, and the development of novel treatment approaches for early-stage disease. He is also involved in research on oligometastatic breast cancer — cases where a limited number of metastatic sites raises the question of whether curative-intent local treatment can improve outcomes alongside systemic therapy.

Quality of life research has been a consistent theme throughout his career, reflecting an understanding that treating breast cancer effectively means addressing not only tumor control but also the impact of treatment on how patients live. He has contributed to studies examining the psychological and physical toll of breast cancer treatment and the optimal ways to communicate treatment choices and their consequences to patients.

Recognition and Awards

Dr. Burstein is a Fellow of the American Society of Clinical Oncology (FASCO) and a Fellow of the American College of Physicians (FACP), two of the most recognized distinctions in medical oncology and internal medicine respectively. He received the George P. Canellos Award for Excellence in Clinical Investigation and Patient Care at Dana-Farber, one of the institution’s most distinguished internal honors, named for the founding chief of medical oncology at Dana-Farber. In 2014 he received the Dana-Farber Clinical Mentor Award, recognizing his sustained commitment to training the next generation of oncologists.

He is described by Dana-Farber as a perennial Top Doctor in the United States for breast cancer care, a designation that reflects not a one-time recognition but a consistent record of peer respect sustained across years.

Dana-Farber’s Breast Oncology Center

Dr. Burstein practices within Dana-Farber’s Breast Oncology Center at the Susan F. Smith Center for Women’s Cancers, which provides comprehensive care across every stage and subtype of breast cancer. The program integrates medical oncology, surgical oncology, radiation oncology, imaging, pathology, genetics, and supportive care in a multidisciplinary model that allows complex cases to be reviewed and managed by a team with deep collective expertise.

Dana-Farber is a National Cancer Institute-designated Comprehensive Cancer Center and consistently ranks among the top cancer centers in the United States. Its breast cancer program is one of the largest referral centers in New England, drawing patients from across the region and nationally for second opinions, clinical trial access, and complex case management.

How to See Dr. Burstein

Dr. Burstein sees patients at Dana-Farber Cancer Institute at 450 Brookline Avenue in the Longwood Medical Area, accessible by the MBTA Green Line D branch at the Longwood Medical Area stop. He also maintains an affiliation with Brigham and Women’s Hospital, located adjacent to Dana-Farber in the same medical campus.

New patient consultations with Dr. Burstein typically require a referral and relevant medical records including pathology reports with molecular marker results, imaging studies, and any prior treatment history. Dana-Farber’s new patient intake team can assist in coordinating records and scheduling.

Preparing for Your Appointment

Patients seeking consultation with Dr. Burstein should bring or arrange to have sent their complete pathology report including receptor status results for estrogen receptor, progesterone receptor, and HER2, as well as any genomic testing results such as Oncotype DX scores. Relevant imaging including mammography, ultrasound, MRI, and staging CT or PET scans with radiology reports should also be provided in advance. A complete record of any prior treatments is essential, particularly if the consultation is for recurrent or metastatic disease.

For patients seeking a second opinion on a newly diagnosed breast cancer, bringing the slides or blocks from the initial biopsy allows Dana-Farber’s pathology team to perform independent review if needed.

Dr. Harold J. Burstein is recognized on the Boston Magazine Top Doctors 2026 list, produced in collaboration with Castle Connolly Medical Ltd. based on peer nomination and review of qualifications, appointments, outcomes, and professional reputation. Boston Health Journal profiles physicians from this list to help Greater Boston residents connect with the region’s most distinguished specialists.